Mezzasalma Advisors, LLC Exelixis, Inc. Transaction History
Mezzasalma Advisors, LLC
- $319 Million
- Q2 2025
A detailed history of Mezzasalma Advisors, LLC transactions in Exelixis, Inc. stock. As of the latest transaction made, Mezzasalma Advisors, LLC holds 56,471 shares of EXEL stock, worth $2.12 Million. This represents 0.78% of its overall portfolio holdings.
Number of Shares
56,471
Previous 50,654
11.48%
Holding current value
$2.12 Million
Previous $1.87 Million
33.1%
% of portfolio
0.78%
Previous 0.67%
Shares
2 transactions
Others Institutions Holding EXEL
# of Institutions
666Shares Held
257MCall Options Held
1.67MPut Options Held
733K-
Black Rock Inc. New York, NY33.5MShares$1.26 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA27.5MShares$1.03 Billion0.02% of portfolio
-
Farallon Capital Management LLC San Francisco, CA22.5MShares$845 Million4.78% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny14.8MShares$556 Million0.88% of portfolio
-
State Street Corp Boston, MA11.8MShares$442 Million0.02% of portfolio
About EXELIXIS, INC.
- Ticker EXEL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 321,832,000
- Market Cap $12.1B
- Description
- Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...